MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Shenoy, Samantha [1 ]
Leahey, Sheryl [2 ]
Catamero, Donna [3 ]
O'Rourke, Lisa [4 ]
Gray, Kathleen [5 ]
Rogers, Stephanie [6 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Mt Sinai Hlth Syst, New York, NY USA
[4] Janssen Res & Dev, Spring House, PA USA
[5] Janssen Res & Dev, Bridgewater, NJ USA
[6] Univ Arkansas Med Sci, Little Rock, AR USA
来源：
ONCOLOGY NURSING FORUM | 2024年 / 51卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Y I38
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    A. M. G. A. Laheij
    N. W. C. J. van de Donk
    Supportive Care in Cancer, 2024, 32
  • [32] RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
    Carlo-Stella, Carmelo
    Mazza, Rita
    Manier, Salomon
    Facon, Thierry
    Yoon, Sung-Soo
    Koh, Youngil
    Harrison, Simon J.
    Er, Jeremy
    Pinto, Antonio
    Volzone, Francesco
    Perrone, Giulia
    Corradini, Paolo
    Cazaubiel, Titouan
    Hulin, Cyrille
    Touzeau, Cyrille
    Moreau, Philippe
    Ocio, Enrique M.
    Gaisan, Carmen Maria Montes
    Popat, Rakesh
    Leong, Sarah
    Offner, Fritz
    Otero, Paula Rodriguez
    Alfonso-Pierola, Ana
    Broeske, Ann-Marie E.
    Dekhtiarenko, Iryna
    Helms, Hans-Joachim
    Belli, Sara
    Rossmann, Eva
    Fauti, Tanja
    Eckmann, Jan
    Moore, Tom
    Schneider, Meike
    Jacob, Wolfgang
    Weisser, Martin
    Hutchings, Martin
    Riley, Caroline Hasselbalch
    BLOOD, 2022, 140
  • [33] Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
    Pan, Darren
    Richter, Joshua
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2024, 19 (06) : 237 - 245
  • [34] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    Laheij, A. M. G. A.
    van de Donk, N. W. C. J.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [35] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [36] Use of Baseline Inflammatory Markers to Predict Toxicities Among Relapsed/Refractory Multiple Myeloma Patients Receiving Ambulatory Teclistamab and Talquetamab
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Shedeck, Audra
    Mooney, Kathy
    Campion, Kathryn
    Raymond, Callan
    Sabirzhanova, Inna
    Anderson, Karen
    Waheed, Sarah
    Huff, Carol Ann
    Ali, Syed Abbas
    Gocke, Christian B.
    Imus, Philip
    BLOOD, 2024, 144 : 7232 - 7233
  • [37] Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma
    Wang, Baohui
    Huang, Xiao
    Sun, Jianming
    Qin, Yurong
    Shang, Hongyan
    Li, Tingting
    Wu, Guojin
    Chen, Min
    Wang, Hailin
    Zhang, Peng
    Jiang, Duqing
    Liu, Tongjun
    Ye, Mi
    Cai, Shengli
    Lai, Shoupeng
    Kang, Xiaoqiang
    Ling, Hong
    BLOOD, 2023, 142
  • [38] Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)xCD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study
    Van De Donk, Niels W. C. J.
    Krishnan, Amrita
    Oriol, A.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Costa, Luciano
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi
    Russell, Jeffery
    Goldberg, Jenna
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S16 - S17
  • [39] Taste Abnormalities Emerging during Anti- Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab
    Fleischer, Anna
    Roll, Magdalena
    Panther, Franziska
    Gelbrich, Goetz
    Reinhardt, Franziska
    Riedhammer, Christine
    Mersi, Julia
    Waldschmidt, Johannes M.
    Einsele, Hermann
    Kortuem, K. Martin
    Maatouk, Imad
    Rasche, Leo
    BLOOD, 2023, 142
  • [40] Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
    Berdeja, Jesus G.
    Krishnan, Amrita Y.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Minnema, Monique C.
    Costa, Luciano J.
    Verona, Raluca
    Girgis, Suzette
    Prior, Thomas
    Hilder, Brandi
    Russell, Jeffery Scott
    Goldberg, Jenna D.
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345